T2382

Vemurafenib (RG7204) is a B-RAF inhibitor that inhibits RAFV600E and c-RAF-1 (IC50=31/48 nM) selectively and potently. Vemurafenib exhibits antitumor activity and is used for the treatment of BRAF V600E mutation-positive melanoma.

BRD4884 is a highly selective and efficient HDAC1 and HDAC2 inhibitor that also inhibits HDAC3, used in research on neurological disorders.

BTG 502 is an alkylamide insecticide that binds to voltage-gated sodium channels and reduces sodium currents, antagonising the activation of sodium channels by Batrachotoxin (BTX).

BRD32048 is the ETV1 transcription factor oncoprotein inhibitor.

Vemurafenib-D7 is the deuterated form of Vemurafenib. Vemurafenib (T2382) (PLX4032; RG7204; RO5185426) is a pioneering and potent selective inhibitor of B-RAF, effectively suppressing the activity of RAFV600E and c-RAF-1 with IC50 values of 31 nM and 48 nM, respectively. It is capable of inducing cellular autophagy (autophagy).